Related Experiment Video
Updated: May 21, 2025
Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
Published on: July 20, 2019
Enhancing nano-immunotherapy of cancer through cGAS-STING pathway modulation
Gaohong Fu1, Yanan Zhao1, Chengqiong Mao2
1School of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou International Campus, Guangzhou 511442, P. R. China. yaliu@scut.edu.cn.
Abstract:
Activation of the cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS)-stimulator of interferon genes (STING) pathway plays a critical role in cancer immunotherapy due to the secretion of multiple pro-inflammatory cytokines and chemokines. Numerous cGAS-STING agonists have been developed for preclinical and clinical trials in tumor immunity. However, several obstacles, such as agonist molecules requiring multiple doses, rapid degradation and poor targeting, weaken STING activation at the tumor site. The advancement of nanotechnology provides an optimized platform for the clinical application of STING agonists. In this review, we summarize events of cGAS-STING pathway activation, the dilemma of delivering STING agonists, and recent advances in the nano-delivery of cGAS-STING agonist formulations for enhancing tumor immunity. Furthermore, we address the future challenges associated with STING-based therapies and offer insights to guide subsequent clinical applications.
Insights
Nanotechnology enhances STING agonist delivery for cancer immunotherapy by overcoming challenges like poor targeting and rapid degradation. This approach aims to improve STING activation at tumor sites for better tumor immunity.
Area of Science:
- Immunology
- Nanotechnology
- Oncology
Background:
- The cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS)-stimulator of interferon genes (STING) pathway is crucial for cancer immunotherapy, inducing pro-inflammatory responses.
- While cGAS-STING agonists show promise, clinical application is hindered by issues like frequent dosing, instability, and poor tumor targeting.
Purpose of the Study:
- To review the mechanisms of cGAS-STING pathway activation in cancer.
- To discuss the challenges in delivering STING agonists effectively to tumors.
- To highlight advancements in nano-delivery systems for STING agonists to enhance tumor immunity.
Main Methods:
- Literature review focusing on cGAS-STING pathway activation.
- Analysis of challenges associated with current STING agonist delivery methods.
- Summary of recent developments in nanotechnology for STING agonist formulation and delivery.
Main Results:
- Nanotechnology offers a promising platform to overcome the limitations of conventional STING agonist delivery.
- Nano-formulations can improve agonist stability, targeting, and sustained release at the tumor site.
- Optimized nano-delivery systems show potential for enhanced STING activation and anti-tumor immunity.
Conclusions:
- Nano-delivery systems represent a significant advancement for STING-based cancer immunotherapies.
- Addressing challenges in nano-formulation and delivery is key to successful clinical translation.
- Future research should focus on optimizing STING-based nano-therapies for improved clinical outcomes in cancer treatment.
More Related Videos
08:35Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles
Published on: January 4, 2012
07:55Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...